Scalper1 News
Generic-drug giant Mylan ( MYL ) announced a $9.9 billion buyout of Swedish counterpart Meda late Wednesday, as it also reported Q4 earnings that missed estimates. The stock tumbled in after-hours trading. Mylan said that the acquisition will be immediately accretive to earnings, adding 35 to 40 cents to EPS next year. That will allow the company to hit its previously stated target of $6.00 a share to earnings a year earlier than the expected 2018. The deal will hike Mylan’s annual revenue by about 25%, and bring $350 million in annual cost savings, Mylan said. Mylan is offering a mixture of cash and stock that adds up to 165 Swedish kronor per Meda share, which including Meda’s net debt adds up to $9.9 billion. “This transaction builds on everything we have put in place around the world, including our recent acquisition of the Abbott ( ABT ) non-U.S. developed markets specialty and branded generics business,” Mylan CEO Heather Bresch said in a statement. “Meda brings us greater scale, breadth and diversity across products, geographies and sales channels, and together we will have an even stronger global commercial infrastructure.” Mylan also said that its Q4 earnings totaled $1.22 a share, up 16% from the year-earlier quarter but 6 cents below analysts’ consensus, according to Thomson Reuters. Revenue climbed 20% to $2.49 billion, more than $200 million short of consensus. For the full 2015, EPS rose 21% to $4.30 while revenue gained 28% to $9.45 billion. Mylan also offered 2016 guidance that assumes that the Meda deal will close at the end of Q3, with $10.5 billion to $11.5 billion in sales and $4.85 to $5.15 in EPS. Analysts did not include Meda in their consensus of $5.00 in EPS and $10.6 billion in sales, but Bresch said the firm is “committed to our 2016 guidance ranges with or without Meda.” Mylan stock, which holds a strong Composite Rating of 89, fell 0.4% in regular trading on the stock market today to close at 50.54. Mylan lost 9% to 45.85 after hours. Scalper1 News
Scalper1 News